NovaBridge Biosciences (NBP) Cash from Investing Activities (2019 - 2024)
NovaBridge Biosciences (NBP) posted quarterly Cash from Investing Activities of -$109000.0 for Q4 2024, up 99.87% quarter-over-quarter from -$81.7 million in Q3 2024.
Analysis
NovaBridge Biosciences (NBP) Cash from Investing Activities (2019 - 2024) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Cash from Investing Activities for 3 consecutive years, with -$109000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Cash from Investing Activities changed N/A year-over-year to -$109000.0; the TTM figure through Dec 2025 stood at -$81.8 million (up 28.88% YoY), while the FY2025 annual figure was $105.0 million, up 177.17% from the prior year.
- Cash from Investing Activities rose to -$109000.0 in Q4 2024 per NBP's latest filing, from -$81.7 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $8.2 million in Q4 2020 and bottomed at -$81.7 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -109,000.00 |
| Sep 30, 2024 | -81.66 Mn |
| Dec 31, 2020 | 8.22 Mn |
| Sep 30, 2020 | -41.43 Mn |
| Dec 31, 2019 | 10.97 Mn |